These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 10866587)

  • 1. Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a-catechol-o-methyl transferase inhibitor.
    Iwuagwu CU; Riley D; Bonoma RA
    Am J Med; 2000 Apr; 108(6):517-8. PubMed ID: 10866587
    [No Abstract]   [Full Text] [Related]  

  • 2. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Henry C; Wilson JA
    Lancet; 1998 Jun; 351(9120):1965-6. PubMed ID: 9654299
    [No Abstract]   [Full Text] [Related]  

  • 3. Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease.
    Sabaté M; Bosch A; Pedrós C; Figueras A
    Ann Pharmacother; 1999 Nov; 33(11):1228-9. PubMed ID: 10573327
    [No Abstract]   [Full Text] [Related]  

  • 4. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Harper J; Vieira B
    Lancet; 1998 Aug; 352(9127):578. PubMed ID: 9716090
    [No Abstract]   [Full Text] [Related]  

  • 5. Neuroleptic malignant-like syndrome and acute hepatitis during tolcapone and clozapine medication.
    Blum MW; Siegel AM; Meier R; Hess K
    Eur Neurol; 2001; 46(3):158-60. PubMed ID: 11598337
    [No Abstract]   [Full Text] [Related]  

  • 6. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
    Roberts JW; Cora-Locatelli G; Bravi D; Amantea MA; Mouradian MM; Chase TN
    Neurology; 1993 Dec; 43(12):2685-8. PubMed ID: 8255478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Akathisia secondary to tolcapone. Report of a case].
    Colorado-Ochoa H
    Gac Med Mex; 2000; 136(5):505-9. PubMed ID: 11080934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroleptic malignant syndrome without neuroleptics.
    Parsa MA; Rohr T; Ramirez LF; Meltzer HY
    J Clin Psychopharmacol; 1990 Dec; 10(6):437-8. PubMed ID: 2286714
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism.
    Jorga KM; Davis TL; Kurth MC; Saint-Hilaire MH; LeWitt PA; Fotteler B; Zürcher G; Rabbia M
    Clin Neuropharmacol; 2000; 23(2):98-105. PubMed ID: 10803800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
    Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroleptic malignant syndrome without neuroleptics.
    Ong KC; Chew EL; Ong YY
    Singapore Med J; 2001 Feb; 42(2):85-8. PubMed ID: 11358199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neuroleptic malignant syndrome after withdrawal of levopoda].
    Cedeno-Veloz B; Areosa Sastre A
    Rev Esp Geriatr Gerontol; 2018; 53(5):299-300. PubMed ID: 29628214
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
    Davis TL; Roznoski M; Burns RS
    Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers.
    Sêdek G; Jorga K; Schmitt M; Burns RS; Leese P
    Clin Neuropharmacol; 1997 Dec; 20(6):531-41. PubMed ID: 9403227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolcapone (Tasmar).
    Robertson S
    CMAJ; 1999 Apr; 160(7):1052, 1056. PubMed ID: 10207353
    [No Abstract]   [Full Text] [Related]  

  • 16. Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations.
    Spahr L; Rubbia-Brandt L; Burkhard PR; Assal F; Hadengue A
    Dig Dis Sci; 2000 Sep; 45(9):1881-4. PubMed ID: 11052337
    [No Abstract]   [Full Text] [Related]  

  • 17. Extending levodopa action: COMT inhibition.
    Martínez-Martín P; O'Brien CF
    Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
    Jorga KM; Nicholl DJ
    Br J Clin Pharmacol; 1999 Sep; 48(3):449-52. PubMed ID: 10510160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
    Jorga KM; Sedek G; Fotteler B; Zürcher G; Nielsen T; Aitken JW
    Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects.
    Russ H; Müller T; Woitalla D; Rahbar A; Hahn J; Kuhn W
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):719-20. PubMed ID: 10619191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.